Skip to Main Content

Back to Press Releases
The Weiner Lab

Wistar's David Weiner, Ph.D., Named President of the International Society for Vaccines

PHILADELPHIA(Jan. 25, 2018)The Wistar Institute is pleased to announce David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute, and the W.W. Smith Charitable Trust Professor in Cancer Research, has been appointed President of the International Society for Vaccines (ISV), an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines.

"As I begin my service as ISV President, it is important to keep in mind that our overarching goals and focus remains the same: serve all of our members and continue to build the society and 'lift all boats' in vaccine research around the globe," Weiner said. "In this regard, we extend our hand and encourage all members to be engaged and energized, and to take an active role in this society-your society."

A renowned molecular immunologist and pioneer in the design and delivery of DNA vaccines, Weiner has more than 25 years of trailblazing research in tumor, immunology and vaccine creation, and has contributed to important achievements in DNA vaccine development. His high-caliber immunology research spans institutes, industry and government: on a national level he was a Food and Drug Administration (FDA) advisor for gene development and globally he is part of multinational research teams working to design vaccines for emerging infectious diseases and pandemics.

Weiner's research has focused extensively on the development of gene-based vaccines, immunotherapies and molecular interventions for the treatment of human and animal diseases. His laboratory is considered one of the founding labs in the field of DNA vaccines, and importantly, was the first to move DNA vaccines to human clinical studies, establishing their initial safety and immunogenicity and opening up this area for clinical development. 

Weiner has more than 70 issued patents in the area of molecular technology, immunization, and immunotherapy. Weiner is also very active in teaching and training and highly committed to the career development of young students, fellows, scientists, and junior faculty. 

An active industry and foundation advisor and spokesperson, Weiner has served on panels and/or as a consultant to numerous pharmaceutical companies, including the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the FDA, and Emily's Entourage, among others. He is the recipient of multiple awards, including the NIH Director's Transformative Research Award in 2012; the Vaccine Industry Excellence Award for Best Academic Research Team at the World Vaccine Congress in 2015; the prestigious Hilleman Lectureship at the Children's Hospital of Philadelphia Grand Rounds in 2015; the Stone Family Award from Abramson Cancer Center, University of Pennsylvania, for his groundbreaking work on DNA vaccines for cancer immunotherapy; and most recently Nature Biotechnology named Weiner as one of the "Top 20 Translational Researchers (#5) " for 2016. 

###

About the International Society for Vaccines:
ISV is a not-for-profit organization that aims to encourage, establish and promote the development and use of vaccines to prevent and control infectious and non-infectious diseases in humans and animals. ISV members come from all over the world, and from all sectors (academia, industry, non-governmental and governmental vaccine institutions, and foundations). The ISV Annual Congress is the world's largest scientific conference in the field of vaccines and covers a broad range of topics related to prophylactic vaccines and immunotherapies for both human and veterinary diseases, and covers basic science immunology through manufacturing, clinical trials, and post-licensure safety and efficacy monitoring.

About The Wistar Institute:
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Print this Page

For press inquiries or more information please contact comm-marketing@wistar.org